Sergey Yu. Martsevich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergey Yu. Martsevich has a total of 409 co-authors. Here are the top co-authors by number of shared publications:
- Natalia P. Kutishenko
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
94 shared publications - Oksana Mikhailovna Drapkina
National Medical Research Center for Therapy and Preventive Medicine, Ministry of Health of Russia
94 shared publications - Yuliya V. Lukina
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
72 shared publications С. Ю. Марцевич
ФГБУ "Национальный медицинский исследовательский центр терапии и профилактической медицины" Минздрава России
66 shared publications- Alexandr V. Zagrebelnyi
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
46 shared publications - M. M. Luk'YAnov
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
45 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5S) , 5123
Basic principles of conducting clinical studies for the evaluation of disease outcomes. Advice for clinicians
This article describes the main methodological approaches to conducting studies related to the evaluation of disease outcomes, including patient survival. It explains the key concepts used in survival analysis. The main stages of planning and conducting a study are considered, as well as the sources of common errors that arise during this process. The article presents the main characteristics of statistical methods used in the analysis of disease outcomes and their clinical interpretation. The primary methods of prognosis based on survival analysis results are reviewed. The role of various types of clinical studies in the evaluation of disease outcomes is discussed. Typical errors occurring in the interpretation of studies assessing disease outcomes are analyzed.
- 10 November 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5S) , 5123
Open AccessBasic principles of conducting clinical studies for the evaluation of disease outcomes. Advice for clinicians
This article describes the main methodological approaches to conducting studies related to the evaluation of disease outcomes, including patient survival. It explains the key concepts used in survival analysis. The main stages of planning and conducting a study are considered, as well as the sources of common errors that arise during this process. The article presents the main characteristics of statistical methods used in the analysis of disease outcomes and their clinical interpretation. The primary methods of prognosis based on survival analysis results are reviewed. The role of various types of clinical studies in the evaluation of disease outcomes is discussed. Typical errors occurring in the interpretation of studies assessing disease outcomes are analyzed.
- Open Access
- 6 November 2026
- Published by Publishing House ABV Press in The Clinician
- Vol. 20 (2) , 38-52
Potentially adverse drug-drug interactions in patients with cardiovascular diseases and non-cardiovascular multimorbidity: data from the CHIP registry
Aim. To evaluate the frequency and types of potential drug-drug interactions (pDDIs) in outpatients with cardiovascular diseases (CVD) and multimorbidity within an ambulatory registry. Material and methods. This observational cross-sectional study was conducted as part of the CHIP (Chuvashia Inappropriate Prescribing) registry, focusing on multimorbid patients over 50 years of age attending a cardiology clinic. Medical history included all medications taken within the two months prior to the study, including therapy for comorbidities. pDDIs were identified primarily using Medscape and Lexicomp® drug interaction checkers, supplemented by screening tools (PROMPT (Prescribing Optimisation Method for Prescribing in Older People), Beers, and STOPP / START criteria Screening Tool of Older Persons’ Prescriptions / Screening Tool to Alert to Right Treatment)) and evidence-based medicine data. Results. The CHIP registry included 300 patients: 120 (40 %) men and 180 (60 %) women (mean age 66.4 ± 7.6 years). pDDIs were identified in 231 patients (77 %). Antihypertensive and antithrombotic agents were the primary drug classes associated with pDDIs, likely due to their frequent inclusion in comorbid cardiovascular therapy. Within the structure of inappropriate prescriptions (n = 662), expert assessment identified 393 pDDIs. Subsequent verification using Lexicomp® and Medscape expanded the number of identified pDDIs to 987. Interactions requiring clinical monitoring predominated (58 % and 58.1 %, respectively). Therapy modification or discontinuation were required in 10.8 % (Lexicomp®) and 11.9 % (Medscape) of pDDIs. Lexicomp® recorded interactions of minimal clinical significance 10 times more frequently than Medscape (13.5 % versus 1.3 %). Additionally, in 11.1 % of cases, assessment via Medscape was not possible due to the absence of specific drugs in its database. Critical drug combinations were registered in 17 cases: 10 (1 %) resulted from physician prescriptions and 7 (0.7 %) from patient self-medication. Conclusion. In the CHIP registry, 77 % of CVD patients had pDDIs, most of which occurred with cardiovascular medications. Identified potentially dangerous combinations resulted from physician prescriptions in 10 cases and self-medication in 7 cases. Automated interaction checkers Lexicomp® and Medscape significantly increase the number of identified pDDIs compared to expert assessment. Lexicomp® features a broader drug database and higher sensitivity for detecting minor pDDIs, while Medscape demonstrates high selectivity for clinically significant interactions.
- 6 November 2026
- Published by Publishing House ABV Press in The Clinician
- Vol. 20 (2) , 38-52
Open AccessPotentially adverse drug-drug interactions in patients with cardiovascular diseases and non-cardiovascular multimorbidity: data from the CHIP registry
Aim. To evaluate the frequency and types of potential drug-drug interactions (pDDIs) in outpatients with cardiovascular diseases (CVD) and multimorbidity within an ambulatory registry. Material and methods. This observational cross-sectional study was conducted as part of the CHIP (Chuvashia Inappropriate Prescribing) registry, focusing on multimorbid patients over 50 years of age attending a cardiology clinic. Medical history included all medications taken within the two months prior to the study, including therapy for comorbidities. pDDIs were identified primarily using Medscape and Lexicomp® drug interaction checkers, supplemented by screening tools (PROMPT (Prescribing Optimisation Method for Prescribing in Older People), Beers, and STOPP / START criteria Screening Tool of Older Persons’ Prescriptions / Screening Tool to Alert to Right Treatment)) and evidence-based medicine data. Results. The CHIP registry included 300 patients: 120 (40 %) men and 180 (60 %) women (mean age 66.4 ± 7.6 years). pDDIs were identified in 231 patients (77 %). Antihypertensive and antithrombotic agents were the primary drug classes associated with pDDIs, likely due to their frequent inclusion in comorbid cardiovascular therapy. Within the structure of inappropriate prescriptions (n = 662), expert assessment identified 393 pDDIs. Subsequent verification using Lexicomp® and Medscape expanded the number of identified pDDIs to 987. Interactions requiring clinical monitoring predominated (58 % and 58.1 %, respectively). Therapy modification or discontinuation were required in 10.8 % (Lexicomp®) and 11.9 % (Medscape) of pDDIs. Lexicomp® recorded interactions of minimal clinical significance 10 times more frequently than Medscape (13.5 % versus 1.3 %). Additionally, in 11.1 % of cases, assessment via Medscape was not possible due to the absence of specific drugs in its database. Critical drug combinations were registered in 17 cases: 10 (1 %) resulted from physician prescriptions and 7 (0.7 %) from patient self-medication. Conclusion. In the CHIP registry, 77 % of CVD patients had pDDIs, most of which occurred with cardiovascular medications. Identified potentially dangerous combinations resulted from physician prescriptions in 10 cases and self-medication in 7 cases. Automated interaction checkers Lexicomp® and Medscape significantly increase the number of identified pDDIs compared to expert assessment. Lexicomp® features a broader drug database and higher sensitivity for detecting minor pDDIs, while Medscape demonstrates high selectivity for clinically significant interactions.
- Open Access
- 18 October 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (9) , 4927
Selective reporting and distorted reporting in research: what are they and what are the consequences?
This article provides a detailed analysis of the term "selective reporting" (SR) and related concepts, such as "distorted reporting" and "publication bias". A classification is proposed that divides SR methods into direct and indirect. It is emphasized that SR is prevalent in virtually all fields of clinical medicine. Sponsor companies play a significant role in the occurrence of SR. Various types of SR are illustrated with specific examples. Special attention is paid to adherence to the fundamental principles of evidence-based medicine as a guarantee for minimizing SR. The author concludes that the current practice of SR prevents the formation of an accurate assessment of the efficacy and safety of specific medicinal products.
- 18 October 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (9) , 4927
Open AccessSelective reporting and distorted reporting in research: what are they and what are the consequences?
This article provides a detailed analysis of the term "selective reporting" (SR) and related concepts, such as "distorted reporting" and "publication bias". A classification is proposed that divides SR methods into direct and indirect. It is emphasized that SR is prevalent in virtually all fields of clinical medicine. Sponsor companies play a significant role in the occurrence of SR. Various types of SR are illustrated with specific examples. Special attention is paid to adherence to the fundamental principles of evidence-based medicine as a guarantee for minimizing SR. The author concludes that the current practice of SR prevents the formation of an accurate assessment of the efficacy and safety of specific medicinal products.
- Open Access
- 28 August 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (8) , 4935
Healthcare fragmentation, multimorbidity, and polypharmacy: a vicious circle of interdisciplinary risks
Aim . To evaluate the prevalence of potential drug-drug interactions (pDDIs) in patients with cardiovascular diseases and non-cardiac comorbidities, and to determine the role of multimorbidity and healthcare fragmentation in the occurrence of these interactions. Material and methods . Based on the Chuvashia Inappropriate Prescribing Study (CHIP) outpatient registry, an in-depth analysis of pharmacotherapy was conducted in 300 multimorbid cardiac patients aged over 50 years, each having at least one non-communicable non-cardiac disease requiring medication. The median drug burden was >9 drugs per patient. Patients were treated by physicians of 23 specialties. Therapy for a single patient could be prescribed by 1 to 5 specialists simultaneously (147 patients were managed by one physician, 98 by a tandem of two, 39 by three, while significant fragmentation involving 4 and 5 specialists was observed in 12 and 4 patients, respectively). The independent contribution of the number of diseases and attending physicians to the accumulation of medication errors was assessed using multivariate statistical modeling. Results . It was established that a monodisciplinary approach (patient management by a single physician) has the highest safety as follows: 32,0% of patients are completely protected from drug interactions. As the fragmentation of healthcare increases, there are following exponential increase in the number of errors: the involvement of 2 specialists reduces the proportion of safe treatment to 19,4%, and the participation of ≥3 physicians reduces the probability of therapy without pDDIs to a critical minimum (7,3%; pConclusion . Healthcare fragmentation is the leading independent factor associated with polypharmacy and decreased safety of pharmacotherapy, significantly exceeding the contribution of multimorbidity. Interdisciplinary outpatient pathways are characterized by critically low continuity. A systemic solution to this problem requires digitalization of medication prescription sheets (implementation of decision support systems) and the reinstatement of the primary care physician as the central coordinator of pharmacotherapy for multimorbid patients.
- 28 August 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (8) , 4935
Open AccessHealthcare fragmentation, multimorbidity, and polypharmacy: a vicious circle of interdisciplinary risks
Aim . To evaluate the prevalence of potential drug-drug interactions (pDDIs) in patients with cardiovascular diseases and non-cardiac comorbidities, and to determine the role of multimorbidity and healthcare fragmentation in the occurrence of these interactions. Material and methods . Based on the Chuvashia Inappropriate Prescribing Study (CHIP) outpatient registry, an in-depth analysis of pharmacotherapy was conducted in 300 multimorbid cardiac patients aged over 50 years, each having at least one non-communicable non-cardiac disease requiring medication. The median drug burden was >9 drugs per patient. Patients were treated by physicians of 23 specialties. Therapy for a single patient could be prescribed by 1 to 5 specialists simultaneously (147 patients were managed by one physician, 98 by a tandem of two, 39 by three, while significant fragmentation involving 4 and 5 specialists was observed in 12 and 4 patients, respectively). The independent contribution of the number of diseases and attending physicians to the accumulation of medication errors was assessed using multivariate statistical modeling. Results . It was established that a monodisciplinary approach (patient management by a single physician) has the highest safety as follows: 32,0% of patients are completely protected from drug interactions. As the fragmentation of healthcare increases, there are following exponential increase in the number of errors: the involvement of 2 specialists reduces the proportion of safe treatment to 19,4%, and the participation of ≥3 physicians reduces the probability of therapy without pDDIs to a critical minimum (7,3%; pConclusion . Healthcare fragmentation is the leading independent factor associated with polypharmacy and decreased safety of pharmacotherapy, significantly exceeding the contribution of multimorbidity. Interdisciplinary outpatient pathways are characterized by critically low continuity. A systemic solution to this problem requires digitalization of medication prescription sheets (implementation of decision support systems) and the reinstatement of the primary care physician as the central coordinator of pharmacotherapy for multimorbid patients.
- Open Access
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4858
Changes in the prognostic value of diabetes in patients after cerebrovascular accident during long-term follow-up: data from the REGION-M registry
Aim . To evaluate the prognostic value of type 2 diabetes (T2D) and to study the relationship between T2D and the risk of mortality at different stages of long-term outpatient follow-up in patients with cerebrovascular accidents (CVA). Material and methods . Within the registry of patients who suffered a stroke in 2012-2017, medical records and discharge summaries after the reference stroke (n=900), as well as outpatient records of patients (n=684), were analyzed. During the outpatient phase of follow-up completed in 2025 within the prospective part of the REGION-M registry, the long-term prognosis of patients after stroke was assessed and the role of type 2 diabetes as a possible prognostic factor was determined at various follow-up stages (2017-2025). The primary endpoint was all-cause death. Results . The entire outpatient phase of observation was divided into four following stages: Stage 1 (median (Me) 22 [13; 38] months) — from the reference stroke to hospital discharge (2017); Stage 2 (Me 57 [45; 71] months) — outpatient follow-up (2017-2020); Stage 3 (Me 79 [68; 95] months) — outpatient follow-up (2020-2022); Stage 4 (Me 114 [103; 128] months) — outpatient follow-up (2022-2025). The median total follow-up time was 9,5 years, during this period. In general, no significant differences in survival were found in patients depending on T2D: hazard ratio (HR) =1,24; 95% confidence interval (CI): 0,985-1,567 (p=0,067), however, Piecewise Cox Regression confirmed a significant association between T2D and the death risk in patients with a history of stroke at stages 1 and 3 of outpatient follow-up as follows: direct association at stage 1 and inverse association at stage 3 (HR=0,67, 95% CI: 0,45-0,99, p=0,044 and HR=1,70 95% CI: 1,07-2,71, p=0,026). Conclusion . In the prospective REGION-M registry part, the long-term prognosis of patients with a history of stroke was assessed at various time points. T2D has an independent negative prognostic value at certain stages of long-term follow-up of such patients.
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4858
Open AccessChanges in the prognostic value of diabetes in patients after cerebrovascular accident during long-term follow-up: data from the REGION-M registry
Aim . To evaluate the prognostic value of type 2 diabetes (T2D) and to study the relationship between T2D and the risk of mortality at different stages of long-term outpatient follow-up in patients with cerebrovascular accidents (CVA). Material and methods . Within the registry of patients who suffered a stroke in 2012-2017, medical records and discharge summaries after the reference stroke (n=900), as well as outpatient records of patients (n=684), were analyzed. During the outpatient phase of follow-up completed in 2025 within the prospective part of the REGION-M registry, the long-term prognosis of patients after stroke was assessed and the role of type 2 diabetes as a possible prognostic factor was determined at various follow-up stages (2017-2025). The primary endpoint was all-cause death. Results . The entire outpatient phase of observation was divided into four following stages: Stage 1 (median (Me) 22 [13; 38] months) — from the reference stroke to hospital discharge (2017); Stage 2 (Me 57 [45; 71] months) — outpatient follow-up (2017-2020); Stage 3 (Me 79 [68; 95] months) — outpatient follow-up (2020-2022); Stage 4 (Me 114 [103; 128] months) — outpatient follow-up (2022-2025). The median total follow-up time was 9,5 years, during this period. In general, no significant differences in survival were found in patients depending on T2D: hazard ratio (HR) =1,24; 95% confidence interval (CI): 0,985-1,567 (p=0,067), however, Piecewise Cox Regression confirmed a significant association between T2D and the death risk in patients with a history of stroke at stages 1 and 3 of outpatient follow-up as follows: direct association at stage 1 and inverse association at stage 3 (HR=0,67, 95% CI: 0,45-0,99, p=0,044 and HR=1,70 95% CI: 1,07-2,71, p=0,026). Conclusion . In the prospective REGION-M registry part, the long-term prognosis of patients with a history of stroke was assessed at various time points. T2D has an independent negative prognostic value at certain stages of long-term follow-up of such patients.
- Open Access
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4828
Five-year outcomes in patients with non-ST-segment elevation acute coronary syndrome in the prospective CONTRAST registry
Aim . To study 5-year outcomes in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in a prospective registry. Material and methods . The Registry of Acute Coronary Syndrome without ST-segment Elevation in the Regional Vascular Center (CONTRAST) included 136 patients admitted to the Sergiyev Posad Vascular Center from October 2018 to March 2019 with a diagnosis of NSTE-ACS. At discharge, the patients were diagnosed with unstable angina (UA) (n=112) or non-ST-segment elevation MI (NSTEMI) (n=24). Five-year outcomes were analyzed. Results . The primary composite endpoint (CEP), including all-cause death, nonfatal myocardial infarction (MI), cerebrovascular accident, and emergency hospitalizations for cardiovascular causes, was recorded in 60 patients. Patients with CEP did not differ in age, sex, or risk factors compared to patients without CEP, but they were more likely to have a history of MI, hypokinesis on echocardiography, and a mildly reduced left ventricular ejection fraction. There were no significant differences in the incidence of CEP between patients with NSTEMI and UA. Multivariate Cox regression analysis showed that independent CEP predictors included hypokinesia area on echocardiography, a moderately reduced left ventricular ejection fraction, pleural effusion in the acute phase, and atrial fibrillation. Patients with NSTEMI and UA did not differ in the likelihood of CEP. PCI during and after the reference hospitalization also did not affect the likelihood of CEP. Conclusion . In a 5-year prospective follow-up study of patients with NSTE-ACS, the likelihood of adverse outcomes was determined primarily by clinical and imaging risk factors identified in the acute phase and was independent of the formal discharge diagnosis (UA or NSTEMI).
- 31 July 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (6) , 4828
Open AccessFive-year outcomes in patients with non-ST-segment elevation acute coronary syndrome in the prospective CONTRAST registry
Aim . To study 5-year outcomes in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in a prospective registry. Material and methods . The Registry of Acute Coronary Syndrome without ST-segment Elevation in the Regional Vascular Center (CONTRAST) included 136 patients admitted to the Sergiyev Posad Vascular Center from October 2018 to March 2019 with a diagnosis of NSTE-ACS. At discharge, the patients were diagnosed with unstable angina (UA) (n=112) or non-ST-segment elevation MI (NSTEMI) (n=24). Five-year outcomes were analyzed. Results . The primary composite endpoint (CEP), including all-cause death, nonfatal myocardial infarction (MI), cerebrovascular accident, and emergency hospitalizations for cardiovascular causes, was recorded in 60 patients. Patients with CEP did not differ in age, sex, or risk factors compared to patients without CEP, but they were more likely to have a history of MI, hypokinesis on echocardiography, and a mildly reduced left ventricular ejection fraction. There were no significant differences in the incidence of CEP between patients with NSTEMI and UA. Multivariate Cox regression analysis showed that independent CEP predictors included hypokinesia area on echocardiography, a moderately reduced left ventricular ejection fraction, pleural effusion in the acute phase, and atrial fibrillation. Patients with NSTEMI and UA did not differ in the likelihood of CEP. PCI during and after the reference hospitalization also did not affect the likelihood of CEP. Conclusion . In a 5-year prospective follow-up study of patients with NSTE-ACS, the likelihood of adverse outcomes was determined primarily by clinical and imaging risk factors identified in the acute phase and was independent of the formal discharge diagnosis (UA or NSTEMI).
- Open Access
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Follow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- 16 July 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 3 (2S) , 89-130
Open AccessFollow-up monitoring of patients with chronic kidney disease by primary care physicians. Guidelines
The high and steadily increasing prevalence of chronic kidney disease (CKD) is a significant medical and social problem. CKD complications significantly reduce quality of life and increase the risk of disability, hospitalization, and death. Timely identification and correction of modifiable risk factors for CKD progression underpins secondary prevention measures. These guidelines describe the management of follow-up monitoring for CKD patients by a general practitioner and incorporate modern approaches to diagnosing disease severity and complications (clinical and paraclinical methods), as well as disease treatment and complication prevention. Application of these guidelines will enable physicians to make informed clinical decisions based on the presented diagnostic algorithm (examinations, consultations). These guidelines are intended for general practitioners, family doctors, and for nursing staff working with these physicians, for paramedics performing the doctor functions of managing follow-up monitoring. These guidelines are also intended for healthcare executives, heads of primary care facilities, and their departments.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 213-220
Adherence to previously prescribed pharmacotherapy in patients undergoing planned inpatient treatment: first results of the PRIMULA study
Aim. To assess adherence to previously prescribed pharmacotherapy among patients with chronic noncommunicable diseases admitted for elective inpatient treatment at a federal medical research center. Material and methods. PRIMULA is a cross-sectional observational study conducted at the National Medical Research Center for Therapy and Preventive Medicine from February 19, 2025 to February 19, 2026. The study included patients admitted to the emergency departmentwho agreed to complete the adherence questionnaire of the National Society of Evidence-Based Pharmacotherapy (NSEBP) and signed informed consent for personal data processing. The questionnaire consisted of 3 modules and required 5-7 minutes to complete. This article presents a preliminary analysis of the data collected during the first 6 months of the study. Results. Among 3,006 patients, men accounted for 53.6%; the median age was 65 [55;72] years. A total of 1,690 (56.2%) patients were married, 453 (15.1%) were smokers, 724 (24.1%) had a disability, and 1,119 (37.2%) were employed. Before hospitalisation, 849 (28.2%) patients had not been followed up in healthcare institutions, 1,318 (43.8%) had been followed up at their local outpatient clinic, 38 (1.3%) at a research clinic, and 801 (26.7%) at other medical institutions of various profiles (pConclusion. Impaired adherence to previously prescribed pharmacotherapy is a clinically significant problem already at the stage of elective hospitalization. The brief NSEBP questionnaire may be used as a screening tool to identify overt adherence problems and signs of hidden non-adherence. The findings support the need for systematic assessment of adherence both in the outpatient setting and at hospital admission.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 213-220
Adherence to previously prescribed pharmacotherapy in patients undergoing planned inpatient treatment: first results of the PRIMULA study
Aim. To assess adherence to previously prescribed pharmacotherapy among patients with chronic noncommunicable diseases admitted for elective inpatient treatment at a federal medical research center. Material and methods. PRIMULA is a cross-sectional observational study conducted at the National Medical Research Center for Therapy and Preventive Medicine from February 19, 2025 to February 19, 2026. The study included patients admitted to the emergency departmentwho agreed to complete the adherence questionnaire of the National Society of Evidence-Based Pharmacotherapy (NSEBP) and signed informed consent for personal data processing. The questionnaire consisted of 3 modules and required 5-7 minutes to complete. This article presents a preliminary analysis of the data collected during the first 6 months of the study. Results. Among 3,006 patients, men accounted for 53.6%; the median age was 65 [55;72] years. A total of 1,690 (56.2%) patients were married, 453 (15.1%) were smokers, 724 (24.1%) had a disability, and 1,119 (37.2%) were employed. Before hospitalisation, 849 (28.2%) patients had not been followed up in healthcare institutions, 1,318 (43.8%) had been followed up at their local outpatient clinic, 38 (1.3%) at a research clinic, and 801 (26.7%) at other medical institutions of various profiles (pConclusion. Impaired adherence to previously prescribed pharmacotherapy is a clinically significant problem already at the stage of elective hospitalization. The brief NSEBP questionnaire may be used as a screening tool to identify overt adherence problems and signs of hidden non-adherence. The findings support the need for systematic assessment of adherence both in the outpatient setting and at hospital admission.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 167-177
Patient-oriented medical care: features and prospects of the patient’s pathway map implementation
The healthcare system operates under defined key performance indicators that must be met. However, its structure remains inherently fragmented, divided into hierarchical tiers of care delivery. Currently, the quality of care is assessed through disease-specific clinical guidelines. There is a critical lack of comprehensive systems capable of evaluating the quality of an individual patient’s journey across the entire healthcare continuum, particularly for those with multiple comorbid conditions. Patient Journey Mapping (PJM) emerges as a potential solution to this challenge. PJM serves as a methodological tool to consolidate patient-centric data generated during care delivery. Its primary benefit lies in enabling multidimensional assessments of the patient’s health status, the healthcare system’s performance, and the appropriateness of prescribed therapies. A foundational requirement for constructing PJM is robust clinical data, which integrates patient-reported outcomes with objective clinical status indicators. Structured medical registries represent the most reliable source of such data. This non-systematic literature review examines the development of patient pathway models based on medical registries and explores their potential applications for stakeholders, including healthcare systems, private clinics, pharmaceutical enterprises, clinicians, and patients. The analysis highlights PJM’s capacity to enhance care coordination, inform value-based healthcare strategies, and facilitate personalized therapeutic interventions.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 167-177
Patient-oriented medical care: features and prospects of the patient’s pathway map implementation
The healthcare system operates under defined key performance indicators that must be met. However, its structure remains inherently fragmented, divided into hierarchical tiers of care delivery. Currently, the quality of care is assessed through disease-specific clinical guidelines. There is a critical lack of comprehensive systems capable of evaluating the quality of an individual patient’s journey across the entire healthcare continuum, particularly for those with multiple comorbid conditions. Patient Journey Mapping (PJM) emerges as a potential solution to this challenge. PJM serves as a methodological tool to consolidate patient-centric data generated during care delivery. Its primary benefit lies in enabling multidimensional assessments of the patient’s health status, the healthcare system’s performance, and the appropriateness of prescribed therapies. A foundational requirement for constructing PJM is robust clinical data, which integrates patient-reported outcomes with objective clinical status indicators. Structured medical registries represent the most reliable source of such data. This non-systematic literature review examines the development of patient pathway models based on medical registries and explores their potential applications for stakeholders, including healthcare systems, private clinics, pharmaceutical enterprises, clinicians, and patients. The analysis highlights PJM’s capacity to enhance care coordination, inform value-based healthcare strategies, and facilitate personalized therapeutic interventions.
- 11 April 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (1) , 45-51
Inappropriate prescribing in patients with cardiovascular diseases and non-cardiac multimorbidity (outpatient registry data)
Aim . To assess the prevalence of inappropriate prescribing (IP) in patients with cardiovascular diseases and concomitant non-cardiac multimorbidity using data from an outpatient registry. Material and methods. The study sequentially included patients aged over 50 years with cardiovascular diseases and at least one concomitant non-cardiac condition requiring drug therapy. Patients completed original questionnaires regarding their medication therapy. Prescriptions were evaluated for inappropriateness based on their compliance with the official Summary of Product Characteristics (SmPC), clinical practice guidelines, and contemporary criteria for inappropriate prescribing. Results . The study included 300 patients (120 men and 180 women). Patients had 2 to 11 comorbidities, with a median (Me) of 5 [4;6]. A total of 2961 medications were prescribed; 2071 prescriptions (69.9%) were classified as IP. At least one IP was identified in 99% of patients, Me 6 [4;9] per patient. The most common categories of IP were: misprescribing — 32% (of which more than half were combinations with potentially harmful drug-drug interactions), underprescribing — 20.1%, and overprescribing — 14%. Two additional types of IP were identified: “careless prescribing” (prescriptions lacking essential information such as dosage, frequency, or administration instructions), accounting for 18.5% of IPs, and “delegated prescribing” (cases where the physician transferred the responsibility for therapeutic decisions to the patient), accounting for 13.9% of IPs. The proportion of IP increased significantly with the total number of prescribed drugs. Of the 103 identified inappropriate drug combinations, 61% were prescribed by a single physician, while 38.4% resulted from uncoordinated prescribing by multiple physicians. Conclusion . The prevalence of IP in patients with cardiovascular diseases and non-cardiac multimorbidity was substantial, at 70% of all prescriptions, consistent with rates in comparable international studies. Misprescribing was the predominant type of IP, with potentially harmful drug-drug interactions being the most common issue, accounting for 19.0% of all inappropriate prescriptions.
- 11 April 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (1) , 45-51
Inappropriate prescribing in patients with cardiovascular diseases and non-cardiac multimorbidity (outpatient registry data)
Aim . To assess the prevalence of inappropriate prescribing (IP) in patients with cardiovascular diseases and concomitant non-cardiac multimorbidity using data from an outpatient registry. Material and methods. The study sequentially included patients aged over 50 years with cardiovascular diseases and at least one concomitant non-cardiac condition requiring drug therapy. Patients completed original questionnaires regarding their medication therapy. Prescriptions were evaluated for inappropriateness based on their compliance with the official Summary of Product Characteristics (SmPC), clinical practice guidelines, and contemporary criteria for inappropriate prescribing. Results . The study included 300 patients (120 men and 180 women). Patients had 2 to 11 comorbidities, with a median (Me) of 5 [4;6]. A total of 2961 medications were prescribed; 2071 prescriptions (69.9%) were classified as IP. At least one IP was identified in 99% of patients, Me 6 [4;9] per patient. The most common categories of IP were: misprescribing — 32% (of which more than half were combinations with potentially harmful drug-drug interactions), underprescribing — 20.1%, and overprescribing — 14%. Two additional types of IP were identified: “careless prescribing” (prescriptions lacking essential information such as dosage, frequency, or administration instructions), accounting for 18.5% of IPs, and “delegated prescribing” (cases where the physician transferred the responsibility for therapeutic decisions to the patient), accounting for 13.9% of IPs. The proportion of IP increased significantly with the total number of prescribed drugs. Of the 103 identified inappropriate drug combinations, 61% were prescribed by a single physician, while 38.4% resulted from uncoordinated prescribing by multiple physicians. Conclusion . The prevalence of IP in patients with cardiovascular diseases and non-cardiac multimorbidity was substantial, at 70% of all prescriptions, consistent with rates in comparable international studies. Misprescribing was the predominant type of IP, with potentially harmful drug-drug interactions being the most common issue, accounting for 19.0% of all inappropriate prescriptions.